Literature mining for the discovery of hidden connections between drugs, genes and diseases

PLoS Computational Biology

Volumn 6, Issue 9, 2010, Pages

  Frijters, Raoul ^a   van Vugt, Marianne ^b   Smeets, Ruben ^b   van Schaik, René ^b   de Vlieg, Jacob ^a,b   Alkema, Wynand ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENES;

CELLULAR PROCESS; CO-OCCURRENCE; DISEASE PROCESS; GENE DRUGS; IN-VITRO; KNOWLEDGE RETRIEVAL; LITERATURE MINING; ROC CURVES; SCIENTIFIC LITERATURE; SIMPLE++;

CELL PROLIFERATION;

3,4 DIHYDROXY N METHYL N NITROSOANILINE; ANIRACETAM; CD74 ANTIGEN; CD8 ANTIGEN; CD8B ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DAMNACANTHAL; INTERFERON BETA SERINE; MILNACIPRAN; MIZOLASTINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PITAVASTATIN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; UNCLASSIFIED DRUG;

ADIPOCYTE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DATA BASE; DATA MINING; DEPRESSION; ENDOTHELIUM CELL; ENZYME INHIBITION; FALSE POSITIVE RESULT; FAMILIAL HYPERCHOLESTEROLEMIA; GENE FUNCTION; GRAVES DISEASE; HUMAN; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; INFORMATION RETRIEVAL; INTRACELLULAR SIGNALING; KNOWLEDGE DISCOVERY; LYMPHOCYTE PROLIFERATION; MEDICAL RESEARCH; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OSTEOBLAST; PREDICTION; PROBABILITY; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SEROTONIN SYNDROME; STATISTICAL ANALYSIS; TARDIVE DYSKINESIA; WITHDRAWAL SYNDROME;

EID: 78049427383     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1000943     Document Type: Article

References (83)

1. Andrade MA, Bork P (2000) Automated extraction of information in molecular biology. FEBS Lett 476: 12-17.
2. Jensen LJ, Saric J, Bork P (2006) Literature mining for the biologist: from information retrieval to biological discovery. Nat Rev Genet 7: 119-129.
3. Andrade MA, Valencia A (1998) Automatic extraction of keywords from scientific text: application to the knowledge domain of protein families. Bioinformatics 14: 600-607.
4. Raychaudhuri S, Schutze H, Altman RB (2002) Using text analysis to identify functionally coherent gene groups. Genome Res 12: 1582-1590.
5. Perez AJ, Perez-Iratxeta C, Bork P, Thode G, Andrade MA (2004) Gene annotation from scientific literature using mappings between keyword systems. Bioinformatics 20: 2084-2091.
6. Homayouni R, Heinrich K, Wei L, Berry MW (2005) Gene clustering by latent semantic indexing of MEDLINE abstracts. Bioinformatics 21: 104-115.
7. Daraselia N, Yuryev A, Egorov S, Novichkova S, Nikitin A, et al. (2004) Extracting human protein interactions from MEDLINE using a full-sentence parser. Bioinformatics 20: 604-611.
8. Shatkay H, Edwards S, Wilbur WJ, Boguski M (2000) Genes, themes and microarrays: using information retrieval for large-scale gene analysis. Proc Int Conf Intell Syst Mol Biol 8: 317-328.
9. Jenssen TK, Laegreid A, Komorowski J, Hovig E (2001) A literature network of human genes for high-throughput analysis of gene expression. Nat Genet 28: 21-28.
10. Chaussabel D, Sher A (2002) Mining microarray expression data by literature profiling. Genome Biol 3: RESEARCH0055.
11. Blaschke C, Oliveros JC, Valencia A (2001) Mining functional information associated with expression arrays. Funct Integr Genomics 1: 256-268.
12. Raychaudhuri S, Chang JT, Imam F, Altman RB (2003) The computational analysis of scientific literature to define and recognize gene expression clusters. Nucleic Acids Res 31: 4553-4560.
13. Frijters R, Verhoeven S, Alkema W, van Schaik R, Polman J (2007) Literaturebased compound profiling: application to toxicogenomics. Pharmacogenomics 8: 1521-1534.
14. Frijters R, Fleuren W, Toonen EJ, Tuckermann JP, Reichardt HM, et al. (2010) Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor. BMC Genomics 11: 359.
15. Alako BT, Veldhoven A, van Baal S, Jelier R, Verhoeven S, et al. (2005) CoPub Mapper: mining MEDLINE based on search term co-publication. BMC Bioinformatics 6: 51.
16. Swanson DR (1986) Fish oil, Raynaud's syndrome, and undiscovered public knowledge. Perspect Biol Med 30: 7-18.
17. DiGiacomo RA, Kremer JM, Shah DM (1989) Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. Am J Med 86: 158-164.
18. Smalheiser NR, Swanson DR (1998) Using ARROWSMITH: a computerassisted approach to formulating and assessing scientific hypotheses. Comput Methods Programs Biomed 57: 149-153.
19. Hristovski D, Peterlin B, Mitchell JA, Humphrey SM (2003) Improving literature based discovery support by genetic knowledge integration. Stud Health Technol Inform 95: 68-73.
20. Swanson DR, Smalheiser NR (1997) An interactive system for finding complementary literatures: A stimulus to scientific discovery. Artif Intell 91: 183-203.
21. Wren JD, Bekeredjian R, Stewart JA, Shohet RV, Garner HR (2004) Knowledge discovery by automated identification and ranking of implicit relationships. Bioinformatics 20: 389-398.
22. Yetisgen-Yildiz M, Pratt W (2006) Using statistical and knowledge-based approaches for literature-based discovery. J Biomed Inform 39: 600-611.
23. Jelier R, Schuemie MJ, Veldhoven A, Dorssers LC, Jenster G, et al. (2008) Anni 2.0: a multipurpose text-mining tool for the life sciences. Genome Biol 9: R96.
24. Fuller SS, Revere D, Bugni PF, Martin GM (2004) A knowledgebase system to enhance scientific discovery: Telemakus. Biomed Digit Libr 1: 2.
25. Frijters R, Heupers B, van Beek P, Bouwhuis M, van Schaik R, et al. (2008) CoPub: a literature-based keyword enrichment tool for microarray data analysis. Nucleic Acids Res 36: W406-410.
26. Rapoport B, McLachlan SM (2007) The thyrotropin receptor in Graves' disease. Thyroid 17: 911-922.
27. Weetman AP (2003) Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol 148: 1-9.
28. Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST (2003) Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62: 492-497.
29. Prokunina L, Padyukov L, Bennet A, de Faire U, Wiman B, et al. (2004) Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum 50: 1770-1773.
30. Newby PR, Roberts-Davies EL, Brand OJ, Heward JM, Franklyn JA, et al. (2007) Tag SNP screening of the PDCD1 gene for association with Graves' disease. Clin Endocrinol (Oxf) 67: 125-128.
31. Hayashi M, Kouki T, Takasu N, Sunagawa S, Komiya I (2008) Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients. Eur J Endocrinol 158: 817-822.
32. Vandenborre K, Van Gool SW, Kasran A, Ceuppens JL, Boogaerts MA, et al. (1999) Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human Tcell activation. Immunology 98: 413-421.
33. Vaidya B, Oakes EJ, Imrie H, Dickinson AJ, Perros P, et al. (2003) CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clin Endocrinol (Oxf) 58: 732-735.
34. Yung E, Cheng PS, Fok TF, Wong GW (2002) CTLA-4 gene A-G polymorphism and childhood Graves' disease. Clin Endocrinol (Oxf) 56: 649-653.
35. Ito T, Ueno T, Clarkson MR, Yuan X, Jurewicz MM, et al. (2005) Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cellmediated alloimmune responses in vivo. J Immunol 174: 6648-6656.
36. Olive D (2006) [Lymphocyte coreceptors]. Med Sci (Paris) 22: 1069-1074.
37. Puozzo C, Panconi E, Deprez D (2002) Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol 17 (Suppl 1): S25-35.
38. Briley M, Prost JF, Moret C (1996) Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 11 (Suppl 4): 9-14.
39. Briley M (2004) Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum Psychopharmacol 19 (Suppl 1): S21-25.
40. Kamata M, Takahashi H, Naito S, Higuchi H (2004) Effectiveness of milnacipran for the treatment of chronic pain: a case series. Clin Neuropharmacol 27: 208-210.
41. Goodman WK (1999) Obsessive-compulsive disorder: diagnosis and treatment. J Clin Psychiatry 60 (Suppl 18): 27-32.
42. Njung'e K, Handley SL (1991) Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br J Pharmacol 104: 105-112.
43. Ichimaru Y, Egawa T, Sawa A (1995) 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol 68: 65-70.
44. Dell'Osso B, Nestadt G, Allen A, Hollander E (2006) Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. J Clin Psychiatry 67: 600-610.
45. Denys D, van der Wee N, van Megen HJ, Westenberg HG (2003) A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 23: 568-575.
46. Sugimoto Y, Tagawa N, Kobayashi Y, Hotta Y, Yamada J (2007) Effects of the serotonin and noradrenaline reuptake inhibitor (SNRI) milnacipran on marble burying behavior in mice. Biol Pharm Bull 30: 2399-2401.
47. Inazu M, Takeda H, Matsumiya T (2003) Functional expression of the norepinephrine transporter in cultured rat astrocytes. J Neurochem 84: 136-144.
48. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, et al. (2004) Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 55: 320-322.
49. McDougle CJ, Epperson CN, Price LH, Gelernter J (1998) Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry 3: 270-273.
50. Miguita K, Cordeiro Q, Shavitt RG, Miguel EC, Vallada H (2006) Association study between the 1287 A/G exonic polymorphism of the norepinephrine transporter (NET) gene and obsessive-compulsive disorder in a Brazilian sample. Rev Bras Psiquiatr 28: 158-159.
51. Kajinami K, Takekoshi N, Saito Y (2003) Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 21: 199-215.
52. Mukhtar RY, Reid J, Reckless JP (2005) Pitavastatin. Int J Clin Pract 59: 239-252.
53. Nicholson AC, Hajjar DP, Zhou X, He W, Gotto AM, Jr., et al. (2007) Antiadipogenic action of pitavastatin occurs through the coordinate regulation of PPARgamma and Pref-1 expression. Br J Pharmacol 151: 807-815.
54. Shao D, Lazar MA (1997) Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem 272: 21473-21478.
55. Tamori Y, Masugi J, Nishino N, Kasuga M (2002) Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 51: 2045-2055.
56. Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964.
57. Imhof BA, Aurrand-Lions M (2004) Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 4: 432-444.
58. Shokawa T, Yoshizumi M, Yamamoto H, Omura S, Toyofuku M, et al. (2006) Induction of heme oxygenase-1 inhibits monocyte chemoattractant protein-1 mRNA expression in U937 cells. J Pharmacol Sci 100: 162-166.
59. Kaneyuki U, Ueda S, Yamagishi S, Kato S, Fujimura T, et al. (2007) Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation. Vascul Pharmacol 46: 286-292.
60. Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, et al. (2002) The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 9: 178-183.
61. Han J, Zhou X, Yokoyama T, Hajjar DP, Gotto AM, Jr., et al. (2004) Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation 109: 790-796.
62. Pelton PD, Zhou L, Demarest KT, Burris TP (1999) PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochem Biophys Res Commun 261: 456-458.
63. Tomiyama K, Nishio E, Watanabe Y (1999) Both wortmannin and simvastatin inhibit the adipogenesis in 3T3-L1 cells during the late phase of differentiation. Jpn J Pharmacol 80: 375-378.
64. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, et al. (2000) Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 271: 688-692.
65. Tabata T, Mine S, Kawahara C, Okada Y, Tanaka Y (2003) Monocyte chemoattractant protein-1 induces scavenger receptor expression and monocyte differentiation into foam cells. Biochem Biophys Res Commun 305: 380-385.
66. Hajer GR, van Haeften TW, Visseren FL (2008) Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 29: 2959-2971.
67. Kakeya H, Imoto M, Takahashi Y, Naganawa H, Takeuchi T, et al. (1993) Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces. II. Structure determination. J Antibiot (Tokyo) 46: 1716-1719.
68. Faltynek CR, Schroeder J, Mauvais P, Miller D, Wang S, et al. (1995) Damnacanthal is a highly potent, selective inhibitor of p56lck tyrosine kinase activity. Biochemistry 34: 12404-12410.
69. Hiramatsu T, Imoto M, Koyano T, Umezawa K (1993) Induction of normal phenotypes in ras-transformed cells by damnacanthal from Morinda citrifolia. Cancer Lett 73: 161-166.
70. Imoto M, Kakeya H, Sawa T, Hayashi C, Hamada M, et al. (1993) Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces. I. Taxonomy, isolation, and characterization. J Antibiot (Tokyo) 46: 1342-1346.
71. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711-715.
72. Fischer HP (2005) Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery. Biotechnol Annu Rev 11: 1-68.
73. Kell DB (2006) Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Discov Today 11: 1085-1092.
74. Butcher EC, Berg EL, Kunkel EJ (2004) Systems biology in drug discovery. Nat Biotechnol 22: 1253-1259.
75. Butcher EC (2005) Can cell systems biology rescue drug discovery? Nat Rev Drug Discov 4: 461-467.
76. Kuhlmann J, Wensing G (2006) The applications of biomarkers in early clinical drug development to improve decision-making processes. Curr Clin Pharmacol 1: 185-191.
77. Wagner JA (2008) Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol 48: 631-651.
78. Colburn WA, Lee JW (2003) Biomarkers, validation and pharmacokineticpharmacodynamic modelling. Clin Pharmacokinet 42: 997-1022.
79. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673-683.
80. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P (2008) Drug target identification using side-effect similarity. Science 321: 263-266.
81. Morgan AA, Lu Z, Wang X, Cohen AM, Fluck J, et al. (2008) Overview of BioCreative II gene normalization. Genome Biol 9 (Suppl 2): S3.
82. Wren JD (2004) Extending the mutual information measure to rank inferred literature relationships. BMC Bioinformatics 5: 145.
83. Fawcett T (2006) An introduction to ROC analysis. Pattern Recognition Letters 27: 861-874.